LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 23

Search options

  1. Article ; Online: Timing of last COVID-19 vaccine dose and SARS-CoV-2 breakthrough infections in fully (boosted) vaccinated healthcare personnel.

    Maltezou, H C / Gamaletsou, M N / Giannouchos, T V / Koukou, D-M / Karapanou, A / Sourri, F / Syrimi, N / Lemonakis, N / Peskelidou, E / Papanastasiou, K / Souliotis, K / Lourida, A / Panagopoulos, P / Hatzigeorgiou, D / Sipsas, N V

    The Journal of hospital infection

    2022  Volume 132, Page(s) 46–51

    Abstract: Aim: To estimate the incidence, timing and severity of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) breakthrough infections in fully vaccinated healthcare personnel (HCP).: Methods: In total, 6496 fully vaccinated HCP were analysed ... ...

    Abstract Aim: To estimate the incidence, timing and severity of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) breakthrough infections in fully vaccinated healthcare personnel (HCP).
    Methods: In total, 6496 fully vaccinated HCP were analysed prospectively from 15
    Results: Overall, 1845 SARS-CoV-2 breakthrough infections occurred (28.4 episodes per 100 HCP), of which 1493 (80.9%) were COVID-19 cases and 352 (19.1%) were asymptomatic infections. Of the 1493 HCP with COVID-19, four were hospitalized for 3-6 days (hospitalization rate among HCP with COVID-19: 0.3%). No intubations or deaths occurred. SARS-CoV-2 breakthrough infections occurred at a mean of 16.2 weeks after the last vaccine dose. Multi-variable regression analyses showed that among the 1845 HCP with a breakthrough infection, the administration of a COVID-19 vaccine dose ≥16.2 weeks before the infection was associated with increased likelihood of developing COVID-19 rather than asymptomatic SARS-CoV-2 infection [odds ratio (OR) 1.58, 95% confidence interval (CI) 1.01-2.46; P=0.045] compared with administering a vaccine dose later. The likelihood of developing COVID-19 compared with asymptomatic infection increased by 7% weekly after the last COVID-19 vaccine dose (OR 1.07, 95% CI 1.03-1.11; P=0.001).
    Conclusion: SARS-CoV-2 breakthrough infections are common among fully (boosted) vaccinated HCP. However, full COVID-19 vaccination offered considerable protection against hospitalization. These findings may contribute to defining the optimal timing for booster vaccinations. More efficient COVID-19 vaccines that will also confer protection against SARS-CoV-2 infection are needed urgently.
    MeSH term(s) Humans ; COVID-19 Vaccines ; COVID-19/epidemiology ; COVID-19/prevention & control ; SARS-CoV-2 ; Breakthrough Infections ; Asymptomatic Infections ; Vaccination ; Delivery of Health Care
    Chemical Substances COVID-19 Vaccines
    Language English
    Publishing date 2022-12-05
    Publishing country England
    Document type Journal Article
    ZDB-ID 779366-2
    ISSN 1532-2939 ; 0195-6701
    ISSN (online) 1532-2939
    ISSN 0195-6701
    DOI 10.1016/j.jhin.2022.11.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1586: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Association between COVID-19 vaccination status, time elapsed since the last vaccine dose, morbidity, and absenteeism among healthcare personnel: A prospective, multicenter study.

    Maltezou, Helena C / Gamaletsou, Maria N / Koukou, Dimitra-Maria / Giannouchos, Theodoros V / Sourri, Flora / Syrimi, Natalia / Karapanou, Amalia / Lemonakis, Nikolaos / Peskelidou, Emmanuela / Papanastasiou, Konstantina / Panagopoulos, Periklis / Souliotis, Kyriakos / Lourida, Athanasia / Hatzigeorgiou, Dimitrios / Sipsas, Nikolaos V

    Vaccine

    2022  Volume 40, Issue 52, Page(s) 7660–7666

    Abstract: Aim: We assessed the impact of COVID-19 vaccination status and time elapsed since the last vaccine dose on morbidity and absenteeism among healthcare personnel (HCP) in the context of a mandatory vaccination policy.: Methods: We followed 7592 HCP ... ...

    Abstract Aim: We assessed the impact of COVID-19 vaccination status and time elapsed since the last vaccine dose on morbidity and absenteeism among healthcare personnel (HCP) in the context of a mandatory vaccination policy.
    Methods: We followed 7592 HCP from November 15, 2021 through April 17, 2022. Full COVID-19 vaccination was defined as a primary vaccination series plus a booster dose at least six months later.
    Results: There were 6496 (85.6 %) fully vaccinated, 953 (12.5 %) not fully vaccinated, and 143 (1.9 %) unvaccinated HCP. A total of 2182 absenteeism episodes occurred. Of 2088 absenteeism episodes among vaccinated HCP with known vaccination status, 1971 (94.4 %) concerned fully vaccinated and 117 (5.6 %) not fully vaccinated. Fully vaccinated HCP had 1.6 fewer days of absence compared to those not fully vaccinated (8.1 versus 9.7; p-value < 0.001). Multivariable regression analyses showed that full vaccination was associated with shorter absenteeism compared to not full vaccination (OR: 0.56; 95 % CI: 0.36-0.87; p-value = 0.01). Compared to a history of ≤ 17.1 weeks since the last dose, a history of > 17.1 weeks since the last dose was associated with longer absenteeism (OR: 1.22, 95 % CI:1.02-1.46; p-value = 0.026) and increased risk for febrile episode (OR: 1.33; 95 % CI: 1.09-1.63; p-value = 0.004), influenza-like illness (OR: 1.53, 95 % CI: 1.02-2.30; p-value = 0.038), and COVID-19 (OR: 1.72; 95 % CI: 1.24-2.39; p-value = 0.001).
    Conclusions: The COVID-19 pandemic continues to impose a considerable impact on HCP. The administration of a vaccine dose in less than four months before significantly protected against COVID-19 and absenteeism duration, irrespective of COVID-19 vaccination status. Defining the optimal timing of boosters is imperative.
    MeSH term(s) Humans ; Influenza Vaccines ; Absenteeism ; Influenza, Human/prevention & control ; COVID-19 Vaccines ; Pandemics ; COVID-19/epidemiology ; COVID-19/prevention & control ; Prospective Studies ; Vaccination ; Health Personnel ; Morbidity ; Delivery of Health Care
    Chemical Substances Influenza Vaccines ; COVID-19 Vaccines
    Language English
    Publishing date 2022-10-26
    Publishing country Netherlands
    Document type Multicenter Study ; Journal Article
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2022.10.049
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1930: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 458: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter study.

    Maltezou, Helena C / Panagopoulos, Periklis / Sourri, Flora / Giannouchos, Theodoros V / Raftopoulos, Vasilios / Gamaletsou, Maria N / Karapanou, Amalia / Koukou, Dimitra-Maria / Koutsidou, Athanasia / Peskelidou, Emmanuela / Papanastasiou, Konstantina / Souliotis, Kyriakos / Lourida, Athanasia / Sipsas, Nikolaos V / Hatzigeorgiou, Dimitrios

    Vaccine

    2021  Volume 39, Issue 48, Page(s) 7021–7027

    Abstract: Aim: Healthcare personnel (HCP) are prioritized for coronavirus disease 2019 (COVID-19) vaccination to protect them and non-disruptive provision of healthcare services. We assessed the impact of the Pfizer-BioNTech vaccine on morbidity and absenteeism ... ...

    Abstract Aim: Healthcare personnel (HCP) are prioritized for coronavirus disease 2019 (COVID-19) vaccination to protect them and non-disruptive provision of healthcare services. We assessed the impact of the Pfizer-BioNTech vaccine on morbidity and absenteeism among HCP.
    Methods: We studied 7445 HCP in five tertiary-care hospitals in Greece from November 15, 2020 through April 18, 2021.
    Results: A total of 910 episodes of absenteeism and 9695 days of absence were recorded during the entire study period. Starting from January 4, 2021, 4823/7445 HCP (64.8%) were fully or partially vaccinated. Overall, 535 episodes of absenteeism occurred from January 4, 2021 through April 18, 2021, including 309 (57.76%) episodes among 2622 unvaccinated HCP and 226 (42.24%) episodes among 4823 vaccinated HCP (11.8 versus 4.7 episodes of absenteeism per 100 HCP, respectively; p-value < 0.001). The mean duration of absenteeism was 11.9 days among unvaccinated HCP compared with 6.9 days among vaccinated HCP (p-value < 0.001). Unvaccinated HCP more frequently developed acute respiratory infection, influenza-like illness, and COVID-19 (p-values < 0.001 for all comparisons). Vaccine effectiveness for fully vaccinated HCP was estimated at 94.16% [confidence interval (CI): 88.50%-98.05%) against COVID-19, 83.62% (CI: 73.36%-90.38%) against SARS-CoV-2 infection (asymptomatic or COVID-19), and 66.42% (CI: 56.86%-74.15%) against absenteeism.
    Conclusion: The COVID-19 pandemic had a considerable impact on healthcare workforce. The Pfizer-BioNTech vaccine significantly reduced morbidity, COVID-19, absenteeism and duration of absenteeism among HCP during a period of high SARS-CoV-2 circulation in the community. It is expected that HCP vaccination will protect them and healthcare services and contain healthcare costs.
    MeSH term(s) Absenteeism ; COVID-19 ; COVID-19 Vaccines ; Delivery of Health Care ; Health Personnel ; Humans ; Morbidity ; Pandemics ; Prospective Studies ; SARS-CoV-2 ; Vaccination
    Chemical Substances COVID-19 Vaccines
    Language English
    Publishing date 2021-10-30
    Publishing country Netherlands
    Document type Journal Article ; Multicenter Study
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2021.10.054
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1930: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 458: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: A geomorphological investigation of the formation and evolution of the Kaiafas sand-dune field (Kyparissiakos Gulf, Ionian Sea, eastern Mediterranean) in the Late Holocene

    Poulos, S. E / Gaki-Papanastasiou, K / Gialouris, P / Ghionis, G / Maroukian, H

    Environmental earth sciences. 2012 June, v. 66, no. 3

    2012  

    Abstract: The present investigation concerns the formation and evolution of the dune field of the central part of the Kyparissiakos Gulf (western coast of Peloponnesos, Greece). This dune field is associated with the Kaiafas lagoon and consists of four dune lines ... ...

    Abstract The present investigation concerns the formation and evolution of the dune field of the central part of the Kyparissiakos Gulf (western coast of Peloponnesos, Greece). This dune field is associated with the Kaiafas lagoon and consists of four dune lines that lie at distances of 600, 200, 100 and 70 m from the coastline. The dune field has developed on top of a barrier beach that formed subsequently to the completion of the last phase of rapid sea level rise, i.e. after 6,000 BP, consisting mostly of medium sand with good sorting, due to its aeolian formation. Assuming a steady wind regime and adequate sediment availability during the late Holocene, a period of approximately 1,350 years has been estimated to be the minimum time required for the formation of the dune field; this formation period may also include intervals when the development processes were more or less intensive. On the basis of radio-carbon dating, secondary fluctuations of air temperature and published information, it is proposed that the 4th (oldest) dune line started forming between the years 400 AD and 1,000 AD, whilst the 1st (youngest) dune line started forming after 1,520 AD. The dune field, especially its youngest line seems to be in equilibrium with its adjacent beach zone and the nearshore hydrodynamics, being beyond the reach of wave run-up. On the other hand, the dune field, over the past decades, has been subjected to intense human intervention (agriculture, construction, forest fires, etc.) that has locally destroyed and/or destabilised part of the dunes. Finally, the expected sea level rise, due to global warming, is undoubtedly a threat to the existence of the dune field.
    Keywords air temperature ; coasts ; dunes ; evolution ; forest fires ; global warming ; hydrodynamics ; sand ; sea level ; wind
    Language English
    Dates of publication 2012-06
    Size p. 955-966.
    Publishing place Springer-Verlag
    Document type Article
    ZDB-ID 2493699-6
    ISSN 1866-6299 ; 1866-6280
    ISSN (online) 1866-6299
    ISSN 1866-6280
    DOI 10.1007/s12665-011-1305-4
    Database NAL-Catalogue (AGRICOLA)

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Renal plasmacytoma.

    Rebelakos, A G / Papanastasiou, K / Apostolikas, N

    British journal of urology

    1995  Volume 75, Issue 4, Page(s) 562

    MeSH term(s) Female ; Humans ; Kidney Neoplasms ; Middle Aged ; Plasmacytoma
    Language English
    Publishing date 1995-04
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 2986-5
    ISSN 1365-2176 ; 0007-1331 ; 1358-8672
    ISSN (online) 1365-2176
    ISSN 0007-1331 ; 1358-8672
    DOI 10.1111/j.1464-410x.1995.tb07291.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui VI Zs.107: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Intermediate dose of intravenous melphalan in advanced multiple myeloma.

    Tsakanikas, S / Papanastasiou, K / Stamatelou, M / Maniatis, A

    Oncology

    1991  Volume 48, Issue 5, Page(s) 369–371

    Abstract: Eighteen patients with advanced multiple myeloma resistant to VAD chemotherapy (vincristine, Adriamycin, dexamethasone) were treated with intravenous melphalan in a single-pulse dose of 50-70 mg/m2. Objective response (greater than or equal to 50% ... ...

    Abstract Eighteen patients with advanced multiple myeloma resistant to VAD chemotherapy (vincristine, Adriamycin, dexamethasone) were treated with intravenous melphalan in a single-pulse dose of 50-70 mg/m2. Objective response (greater than or equal to 50% reduction of the monoclonal protein) was observed in 9 patients. The median duration of remission in the responding patients was 6 months and the median survival 11.5 months. The main toxicity noted was bone marrow suppression. We conclude that intermediate doses of intravenous melphalan are a useful therapeutic modality in refractory or relapsing myeloma patients.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Dexamethasone/administration & dosage ; Doxorubicin/administration & dosage ; Female ; Humans ; Male ; Melphalan/administration & dosage ; Multiple Myeloma/drug therapy ; Vincristine/administration & dosage
    Chemical Substances Vincristine (5J49Q6B70F) ; Dexamethasone (7S5I7G3JQL) ; Doxorubicin (80168379AG) ; Melphalan (Q41OR9510P)
    Language English
    Publishing date 1991
    Publishing country Switzerland
    Document type Clinical Trial ; Journal Article
    ZDB-ID 250101-6
    ISSN 1423-0232 ; 0030-2414
    ISSN (online) 1423-0232
    ISSN 0030-2414
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.151: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Intermediate-dose melphalan for refractory myeloma.

    Maniatis, A / Tsakanikas, S / Stamatellou, M / Papanastasiou, K

    Blood

    1989  Volume 74, Issue 3, Page(s) 1177

    MeSH term(s) Adult ; Aged ; Drug Administration Schedule ; Humans ; Melphalan/therapeutic use ; Middle Aged ; Multiple Myeloma/drug therapy
    Chemical Substances Melphalan (Q41OR9510P)
    Language English
    Publishing date 1989-08-15
    Publishing country United States
    Document type Comment ; Letter
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Chemotherapy of resistant multiple myeloma with vincristine, adriamycin and dexamethasone (VAD).

    Maniatis, A / Stamatellou, M / Papanastasiou, K

    Chemioterapia : international journal of the Mediterranean Society of Chemotherapy

    1987  Volume 6, Issue 2 Suppl, Page(s) 727–728

    MeSH term(s) Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Dexamethasone/administration & dosage ; Doxorubicin/administration & dosage ; Drug Resistance ; Humans ; Multiple Myeloma/drug therapy ; Multiple Myeloma/pathology ; Neoplasm Staging ; Vincristine/administration & dosage
    Chemical Substances Vincristine (5J49Q6B70F) ; Dexamethasone (7S5I7G3JQL) ; Doxorubicin (80168379AG)
    Language English
    Publishing date 1987-06
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 604944-8
    ISSN 0392-906X
    ISSN 0392-906X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1827: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group.

    Zervas, K / Pouli, A / Perifanis, V / Papanastasiou, K / Chatziyianni, M / Mitsouli, C / Maniatis, A

    European journal of haematology

    1996  Volume 57, Issue 2, Page(s) 142–148

    Abstract: Results of studies using IFN-alpha treatment for maintaining remission and prolonging survival in multiple myeloma (MM) are in conflict and trials seeking optimum use for this biological response modifier are continuing. Between 1989 and 1993 a ... ...

    Abstract Results of studies using IFN-alpha treatment for maintaining remission and prolonging survival in multiple myeloma (MM) are in conflict and trials seeking optimum use for this biological response modifier are continuing. Between 1989 and 1993 a prospective randomized multicentre trial was undertaken to evaluate the role of the combination of IFN-alpha with chemotherapy (CT) in maintenance treatment of MM. For remission induction, in patients 65 yr or younger, we used VAD (group A) and for the remaining Melphalan and Prednisone (MP) (group B). For maintenance, patients were randomized to receive IFN-alpha 3 x 10(6) i.u. s.c. t.i.w. (group I) or alternating monthly cycles of IFN-alpha and CT. The CT cycles were also alternated (VAD, MP, CP) in an effort to prevent the development of multidrug resistance. Median survival of the two maintenance groups from randomization (36 months for group I and 31 months for group II, p = 0.3) as well as response duration (13 months in group I and 15 months in group II, p = 0.95) were similar. Toxicities were more pronounced both with VAD induction and in the combination maintenance arm. The addition of chemotherapy to the IFN maintenance regimen in MM did not have an advantage over IFN alone.
    MeSH term(s) Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Combined Modality Therapy ; Dexamethasone ; Disease-Free Survival ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Drug Administration Schedule ; Female ; Humans ; Immunologic Factors/therapeutic use ; Interferon-alpha/therapeutic use ; Life Tables ; Male ; Melphalan/administration & dosage ; Melphalan/adverse effects ; Middle Aged ; Multiple Myeloma/drug therapy ; Multiple Myeloma/mortality ; Multiple Myeloma/therapy ; Prednisone/administration & dosage ; Prednisone/adverse effects ; Prognosis ; Proportional Hazards Models ; Prospective Studies ; Remission Induction ; Survival Rate ; Vincristine/administration & dosage ; Vincristine/adverse effects
    Chemical Substances Immunologic Factors ; Interferon-alpha ; Vincristine (5J49Q6B70F) ; Dexamethasone (7S5I7G3JQL) ; Doxorubicin (80168379AG) ; Melphalan (Q41OR9510P) ; Prednisone (VB0R961HZT)
    Language English
    Publishing date 1996-08
    Publishing country England
    Document type Clinical Trial ; Comparative Study ; Journal Article ; Multicenter Study ; Randomized Controlled Trial
    ZDB-ID 392482-8
    ISSN 1600-0609 ; 0902-4441
    ISSN (online) 1600-0609
    ISSN 0902-4441
    DOI 10.1111/j.1600-0609.1996.tb01352.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 323: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Intermediate Dose of Intravenous Melphalan in Advanced Multiple Myeloma

    Tsakanikas, S. / Papanastasiou, K. / Stamatelou, M. / Maniatis, A.

    Oncology 1991

    1991  Volume 48, Issue 5, Page(s) 369–371

    Abstract: Eighteen patients with advanced multiple myeloma resistant to VAD chemotherapy (vincristine, Adriamycin, dexamethasone) were treated with intravenous melphalan in a single-pulse dose of 50-70 mg/m2. Objective response (≥50% reduction of the monoclonal ... ...

    Abstract Eighteen patients with advanced multiple myeloma resistant to VAD chemotherapy (vincristine, Adriamycin, dexamethasone) were treated with intravenous melphalan in a single-pulse dose of 50-70 mg/m2. Objective response (≥50% reduction of the monoclonal protein) was observed in 9 patients. The median duration of remission in the responding patients was 6 months and the median survival 11.5 months. The main toxicity noted was bone marrow suppression. We conclude that intermediate doses of intravenous melphalan are a useful therapeutic modality in refractory or relapsing myeloma patients.
    Keywords Intravenous melphalan ; Myeloma
    Language English
    Publisher S. Karger AG
    Publishing place Basel
    Publishing country Switzerland
    Document type Article
    ZDB-ID 250101-6
    ISSN 1423-0232 ; 0030-2414 ; 0030-2414
    ISSN (online) 1423-0232
    ISSN 0030-2414
    DOI 10.1159/000226961
    Database Karger publisher's database

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.151: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top